These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 30556911

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
    Nakagawa H, Nemoto O, Igarashi A, Saeki H, Oda M, Kabashima K, Nagata T.
    J Allergy Clin Immunol; 2019 Dec; 144(6):1575-1583. PubMed ID: 31425780
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
    Merola JF, Elewski B, Tatulych S, Lan S, Tallman A, Kaur M.
    J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Tofacitinib].
    Döker S, Dewenter M, El-Armouche A.
    Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
    Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, Horneff G, Smolewska E, Vehe RK, Hazra A, Wang R, Mebus CA, Alvey C, Lamba M, Krishnaswami S, Stock TC, Wang M, Suehiro R, Martini A, Lovell DJ, Pediatric Rheumatology International Trials Organization (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Pediatr Rheumatol Online J; 2017 Dec 28; 15(1):86. PubMed ID: 29282090
    [Abstract] [Full Text] [Related]

  • 27. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D, O'Dell KM, Bandy JL, Boyce EG.
    Ann Pharmacother; 2013 Nov 28; 47(11):1524-31. PubMed ID: 24285764
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
    Lamba M, Wang R, Fletcher T, Alvey C, Kushner J, Stock TC.
    J Clin Pharmacol; 2016 Nov 28; 56(11):1362-1371. PubMed ID: 26970526
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K, Gulin SJ, Mokos ZB, Ceovic R.
    Curr Med Chem; 2017 May 31; 24(11):1158-1167. PubMed ID: 28088907
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY, Craiglow BG, King BA.
    J Am Acad Dermatol; 2018 Feb 31; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
    Tom WL, Van Syoc M, Chanda S, Zane LT.
    Pediatr Dermatol; 2016 Feb 31; 33(2):150-9. PubMed ID: 26777394
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese.
    Suzuki M, Tse S, Hirai M, Kurebayashi Y.
    Kobe J Med Sci; 2017 May 09; 62(6):E150-E161. PubMed ID: 28490712
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
    Nakagawa H, Nemoto O, Igarashi A, Nagata T.
    Br J Dermatol; 2018 Feb 09; 178(2):424-432. PubMed ID: 28960254
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
    Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL, US Tacrolimus Ointment Study Group.
    Pediatrics; 2008 Dec 09; 122(6):e1210-8. PubMed ID: 19015204
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.